---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-248476"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2022-09-22T23:59:59+00:00"
generated_at: "2026-06-23T08:06:09.450918+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion reports BMF-219 preclinical data: HbA1c reduction of 3.5% vs. liraglutide's 1.7% in T2D rat model

## Summary
- BMF-219 lowered HbA1c by 3.5% vs. liraglutide 1.7% in ZDF rat model; effect maintained through 2-week drug washout.
- BMF-219 restored HOMA-B index to normal range (>201) over 4 weeks, indicating improved beta-cell function.
- BMF-219 treatment resulted in 13% body weight reduction over 4 weeks and lowered total cholesterol and triglycerides.
- Company reaffirms IND submission for BMF-219 in type 2 diabetes in second half of 2022.
- Data presented at EASD Annual Meeting on September 20, 2022 in Stockholm, Sweden.

## SEC filing metadata
- accession: 0001193125-22-248476
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2022-09-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312522248476/0001193125-22-248476-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312522248476/d376137d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-248476
- JSON: https://secwatch.observer/filing/0001193125-22-248476.json
- Plain text: https://secwatch.observer/filing/0001193125-22-248476.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.